Suppr超能文献

用于膝关节腔内注射以保守治疗骨关节炎的间充质基质细胞制品

Mesenchymal stromal cell products for intra-articular knee injections for conservative management of osteoarthritis.

作者信息

Andia Isabel, Maffulli Nicola

机构信息

Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London E1 4DG, UK.

Regenerative Therapies, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.

出版信息

Ther Adv Musculoskelet Dis. 2021 Feb 18;13:1759720X21996953. doi: 10.1177/1759720X21996953. eCollection 2021.

Abstract

Sports injuries and secondary joint problems, mainly of the knee, are common, especially in sports associated with high impact activities and/or torsional loading. The consequences can be career ending in elite athletes and reduce exercise activities in recreational people. Various cell products can be injected intra-articularly. First, fresh cellular mixtures can be prepared and injected in the same day, such as stromal vascular fraction of adipose tissue (SVF) and bone marrow concentrates (BMCs). Second, autologous mesenchymal stromal cells (MSCs) can be isolated from BMCs or SVF and, after several weeks of laboratory expansion, several millions of MSCs can be obtained for intra-articular injection. Finally, allogeneic MSCs from the bone marrow, adipose tissue or perinatal tissues of selected donors constitute an 'off-the-shelf' experimental treatment for injection delivery in patients with osteoarthritis of the knee. The perceived efficacy of all these products is based on the hypothesis of a paracrine mechanism of action: when living cells are delivered within the joint, they establish a molecular cross-talk with immune cells and local cell phenotypes, thereby modulating inflammation with subsequent modifications in the catabolic/degenerative milieu. Current clinical research examines whether injection delivery of MSCs translates into actual clinical benefits. Overall, clinical studies lack the quality needed to answer major research questions, including clinical and structural efficacy, optimal cell dose, and number of injections and specific protocol for cell delivery. Poor experimental designs are exacerbated by the diversity of patient phenotypes that hinder comparisons between treatments. Further understanding of disease pathology is paramount to develop potent function assays and understand whether the host tissue, the cell product or both should be primed before MSCs are injected intra-articularly.

摘要

运动损伤和继发性关节问题,主要是膝关节问题,很常见,尤其是在与高冲击活动和/或扭转负荷相关的运动中。其后果可能导致精英运动员的职业生涯结束,并减少普通运动人群的锻炼活动。多种细胞产品可进行关节内注射。首先,可以制备新鲜细胞混合物并在同一天注射,如脂肪组织的基质血管成分(SVF)和骨髓浓缩物(BMC)。其次,可以从BMC或SVF中分离出自体间充质基质细胞(MSC),经过数周的实验室扩增后,可获得数百万个MSC用于关节内注射。最后,来自选定供体的骨髓、脂肪组织或围产期组织的同种异体MSC构成一种“现货”实验性治疗方法,用于膝关节骨关节炎患者的注射给药。所有这些产品的预期疗效基于旁分泌作用机制的假设:当活细胞被输送到关节内时,它们与免疫细胞和局部细胞表型建立分子相互作用,从而调节炎症,随后改变分解代谢/退行性环境。目前的临床研究正在考察MSC的注射给药是否能转化为实际的临床益处。总体而言,临床研究缺乏回答主要研究问题所需的质量,这些问题包括临床和结构疗效、最佳细胞剂量、注射次数以及细胞给药的具体方案。患者表型多样性加剧了实验设计的不足,阻碍了不同治疗方法之间的比较。进一步了解疾病病理学对于开发有效的功能测定方法以及理解在关节内注射MSC之前是否应先对宿主组织、细胞产品或两者进行预处理至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282c/7897835/149ede5c8fc8/10.1177_1759720X21996953-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验